ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0498

Background Mycophenolate (MMF) Treatment Is Associated with Improved Outcomes in a Phase 3 Trial of Lenabasum in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Abstract Number: 1746

Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
Abstract Number: 1396

Baricitinib in Relapsing Giant Cell Arteritis: A Prospective Open-Label Single-Institution Study
Abstract Number: 1763

Baricitinib Reduces Proinflammatory Serum Cytokines in Patients with Systemic Lupus Erythematosus 
Abstract Number: 0603

Barriers and Potential Solutions in the Recruitment and Retention of Older Patients in Clinical Trials – Lessons Learned from Six Large Multi-center Randomized Controlled Trials
Abstract Number: 1168

Barriers to Effectiveness of Non-surgical Treatments for Knee Osteoarthritis in a Diverse Racial/Ethnic Population: A Nominal Group Qualitative Study
Abstract Number: 1642

Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy
Abstract Number: 0214

Baseline Cam or Pincer Morphology Is Associated with Loss of Quantitative Joint Space Width at the Hip: The Johnston County Osteoarthritis Project
Abstract Number: 0766

Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Abstract Number: 0934

Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-Radiographic Axial Spondylarthritis Patients Through 52 Weeks: Data from 3 Phase III, Randomized, Controlled Trials
Abstract Number: 0821

Baseline Characteristics Predictive of Remission in Patients with RA Following Treatment with IV Abatacept: Post Hoc Analysis of a Real-world Observational Study
Abstract Number: 0807

Baseline Coping Strategies as Predictors of Outcomes in Patients with Early-onset Rheumatoid Arthritis (RA)
Abstract Number: 1225

Baseline Extracellular Matrix Biomarkers Predict Abatacept Treatment Response in MTX-Naive, ACPA+ Patients with Early RA
Abstract Number: 1444

Baseline Factors Associated with the Development of Nausea and Alopecia over One Year in Patients Starting Methotrexate for Rheumatoid Arthritis
Abstract Number: 0540

Behavioral Deficits May Precede Influx of Brain-Infiltrating Macrophages in Neuropsychiatric Symptoms of Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].